Features of Effective T Cell-Inducing Vaccines Against Chronic Viral Infections

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2018 Mar 6

PMID 29503649

Citations 73

Authors

Eleni Panagioti

Paul Klenerman

Lian N Lee

Sjoerd H van der Burg

Ramon Arens

Affiliations

Soon will be listed here.

Abstract

For many years, the focus of prophylactic vaccines was to elicit neutralizing antibodies, but it has become increasingly evident that T cell-mediated immunity plays a central role in controlling persistent viral infections such as with human immunodeficiency virus, cytomegalovirus, and hepatitis C virus. Currently, various promising prophylactic vaccines, capable of inducing substantial vaccine-specific T cell responses, are investigated in preclinical and clinical studies. There is compelling evidence that protection by T cells is related to the magnitude and breadth of the T cell response, the type and homing properties of the memory T cell subsets, and their cytokine polyfunctionality and metabolic fitness. In this review, we evaluated these key factors that determine the qualitative and quantitative properties of CD4 and CD8 T cell responses in the context of chronic viral disease and prophylactic vaccine development. Elucidation of the mechanisms underlying T cell-mediated protection against chronic viral pathogens will facilitate the development of more potent, durable and safe prophylactic T cell-based vaccines.

Citing Articles

Development of a multi-epitope vaccine candidate to combat SARS-CoV-2 and dengue virus co-infection through an immunoinformatic approach.

Mandal S, Chanu W, Natarajaseenivasan K Front Immunol. 2025; 16:1442101.

PMID: 40079004 PMC: 11897530. DOI: 10.3389/fimmu.2025.1442101.

Mini-review on the therapeutic vaccines targeting chronic infectious diseases: Evaluation system of therapeutic vaccines targeting HPV and EBV-related cancers.

Woo S, Park P, An T, Fatima M, Moon Y, Lee S Hum Vaccin Immunother. 2025; 21(1):2457187.

PMID: 39957237 PMC: 11834422. DOI: 10.1080/21645515.2025.2457187.

Cross-protection against homo and heterologous influenza viruses via intranasal administration of an HA chimeric multiepitope nanoparticle vaccine.

Zhao Y, Liu J, Peng C, Guo S, Wang B, Chen L J Nanobiotechnology. 2025; 23(1):77.

PMID: 39905416 PMC: 11792681. DOI: 10.1186/s12951-025-03122-6.

Emerging Frontiers in Colorectal Cancer Therapy: From Targeted Molecules to Immunomodulatory Breakthroughs and Cell-Based Approaches.

Fatemi N, Mirbahari S, Tierling S, Sanjabi F, Shahrivari S, AmeliMojarad M Dig Dis Sci. 2025; .

PMID: 39869166 DOI: 10.1007/s10620-024-08774-2.

SARS-CoV-2 inflammation durably imprints memory CD4 T cells.

Gray-Gaillard S, Solis S, Chen H, Monteiro C, Ciabattoni G, Samanovic M Sci Immunol. 2024; 9(96):eadj8526.

PMID: 38905326 PMC: 11824880. DOI: 10.1126/sciimmunol.adj8526.

References

Ahmed R, Gray D . Immunological memory and protective immunity: understanding their relation. Science. 1996; 272(5258):54-60. DOI: 10.1126/science.272.5258.54. View

Wang R, Dillon C, Shi L, Milasta S, Carter R, Finkelstein D . The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity. 2011; 35(6):871-82. PMC: 3248798. DOI: 10.1016/j.immuni.2011.09.021. View

Panagioti E, Boon L, Arens R, van der Burg S . Enforced OX40 Stimulation Empowers Booster Vaccines to Induce Effective CD4 and CD8 T Cell Responses against Mouse Cytomegalovirus Infection. Front Immunol. 2017; 8:144. PMC: 5316540. DOI: 10.3389/fimmu.2017.00144. View

Sedger L, McDermott M . TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future. Cytokine Growth Factor Rev. 2014; 25(4):453-72. DOI: 10.1016/j.cytogfr.2014.07.016. View

Che J, Daniels K, Selin L, Welsh R . Heterologous Immunity and Persistent Murine Cytomegalovirus Infection. J Virol. 2016; 91(2). PMC: 5215326. DOI: 10.1128/JVI.01386-16. View

Park S, Shin E, Capone S, Caggiari L, De Re V, Nicosia A . Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus. Gastroenterology. 2012; 143(4):1048-60.e4. PMC: 3458177. DOI: 10.1053/j.gastro.2012.06.005. View

Bartholdy C, Kauffmann S, Christensen J, Thomsen A . Agonistic anti-CD40 antibody profoundly suppresses the immune response to infection with lymphocytic choriomeningitis virus. J Immunol. 2007; 178(3):1662-70. DOI: 10.4049/jimmunol.178.3.1662. View

Liu J, Zhang E, Ma Z, Wu W, Kosinska A, Zhang X . Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog. 2014; 10(1):e1003856. PMC: 3879364. DOI: 10.1371/journal.ppat.1003856. View

Rosenblum M, Way S, Abbas A . Regulatory T cell memory. Nat Rev Immunol. 2015; 16(2):90-101. PMC: 5113825. DOI: 10.1038/nri.2015.1. View

10.

Redeker A, Welten S, Baert M, Vloemans S, Tiemessen M, Staal F . The Quantity of Autocrine IL-2 Governs the Expansion Potential of CD8+ T Cells. J Immunol. 2015; 195(10):4792-801. DOI: 10.4049/jimmunol.1501083. View

11.

Morabito K, Ruckwardt T, Redwood A, Moin S, Price D, Graham B . Intranasal administration of RSV antigen-expressing MCMV elicits robust tissue-resident effector and effector memory CD8+ T cells in the lung. Mucosal Immunol. 2016; 10(2):545-554. PMC: 5123975. DOI: 10.1038/mi.2016.48. View

12.

Karaki S, Anson M, Tran T, Giusti D, Blanc C, Oudard S . Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors. Vaccines (Basel). 2016; 4(4). PMC: 5192357. DOI: 10.3390/vaccines4040037. View

13.

Billeskov R, Wang Y, Solaymani-Mohammadi S, Frey B, Kulkarni S, Andersen P . Low Antigen Dose in Adjuvant-Based Vaccination Selectively Induces CD4 T Cells with Enhanced Functional Avidity and Protective Efficacy. J Immunol. 2017; 198(9):3494-3506. PMC: 5392729. DOI: 10.4049/jimmunol.1600965. View

14.

Brave A, Boberg A, Gudmundsdotter L, Rollman E, Hallermalm K, Ljungberg K . A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice. Mol Ther. 2007; 15(9):1724-33. DOI: 10.1038/sj.mt.6300235. View

15.

Williams M, Tyznik A, Bevan M . Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature. 2006; 441(7095):890-3. PMC: 2776073. DOI: 10.1038/nature04790. View

16.

Ahmed R, Roger L, Costa Del Amo P, Miners K, Jones R, Boelen L . Human Stem Cell-like Memory T Cells Are Maintained in a State of Dynamic Flux. Cell Rep. 2016; 17(11):2811-2818. PMC: 5186732. DOI: 10.1016/j.celrep.2016.11.037. View

17.

Croft M . The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol. 2009; 9(4):271-85. PMC: 2737409. DOI: 10.1038/nri2526. View

18.

Santra S, Liao H, Zhang R, Muldoon M, Watson S, Fischer W . Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med. 2010; 16(3):324-8. PMC: 2834806. DOI: 10.1038/nm.2108. View

19.

Swaminathan G, Thoryk E, Cox K, Meschino S, Dubey S, Vora K . A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens. Vaccine. 2015; 34(1):110-9. DOI: 10.1016/j.vaccine.2015.10.132. View

20.

Khan U, Ali F, Khurram M, Zaka A, Hadid T . Immunotherapy-associated autoimmune hemolytic anemia. J Immunother Cancer. 2017; 5:15. PMC: 5319184. DOI: 10.1186/s40425-017-0214-9. View